Multibagger Selection: Perplexity's picks
Perplexity picked LIFE, DAVE, PGY, MAZE, FOUR with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Perplexity |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | LIFE | — | 62% | — | — |
| 2 | DAVE | — | 58% | — | — |
| 3 | PGY | — | 55% | — | — |
| 4 | MAZE | — | 45% | — | — |
| 5 | FOUR | — | 40% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +1.46% | +2.39% | 1.17x | 0 |
The model's market view
The backdrop for US small and mid-cap multibagger candidates is constructive but selective: Russell 2000 earnings growth has been strong in 2026, small-cap earnings are expected to outpace large caps in 2027, and AI infrastructure, financial technology, and reshoring-related industrials are providing tangible demand catalysts. The main risks are elevated valuations in AI-linked names, financing-dependent biotechnology, and macro sensitivity; the best asymmetry appears in companies with already visible revenue acceleration, operating leverage, and funded runway rather than purely thematic exposure.
Why each pick
LIFE
Ethos is a rare small/mid-cap compounder with revenue more than doubling while already generating positive operating cash flow. Q2 2026 revenue was $189.6 million, up 113% year over year, and management raised FY2026 revenue guidance to $727-731 million, implying about 88% growth at the midpoint. A $2.7 billion market capitalization leaves substantial upside capacity if the company sustains even a fraction of current growth while converting revenue into durable earnings and free cash flow. This is a high-execution-risk growth thesis, not a valuation-driven deep value case.
DAVE
Dave combines rapid revenue growth, strong adjusted EBITDA growth, positive free cash flow, and a credible path to further operating leverage. Q2 2026 revenue rose 30% year over year to $170.8 million while adjusted EBITDA rose 48% to $76 million, showing margin expansion. At about $4.1 billion market capitalization, the company is near the upper limit of the required size band, but its profitability and cash generation distinguish it from most high-growth fintechs. The principal issue is that a 3x outcome already requires a very large enterprise value, so the scenario is exceptional rather than merely plausible.
PGY
Pagaya offers a more balanced growth-plus-profitability profile than most AI-fintech candidates. Q2 2026 network volume rose 33% year over year to a record $3.5 billion, revenue and other income rose 19% to $387 million, and GAAP net income attributable to shareholders reached a record $45 million. With a market capitalization near $1.65 billion, the shares retain more upside capacity than Dave or Ethos if volume growth, fee revenue, and funding access continue to scale.
MAZE
Maze is a clinical-stage biotechnology selection with unusually strong balance-sheet protection: approximately $528 million in cash and a stated runway into 2029. Its lead asset, MZE829, is in Phase 2 for APOL1-mediated kidney disease, an indication with no approved therapy, and Vertex's positive mid-stage data for inaxaplin has validated the broader commercial opportunity. The upside case depends on clinical execution rather than current revenue, so confidence is lower and the 3x scenario is exceptional.
FOUR
Shift4 is included as the fifth-best available candidate because it combines a mid-cap size within the required band, a low forward P/E of 6.3, projected 2026-2028 revenue CAGR of 10.7%, and projected EPS CAGR of 18.6% according to FactSet data cited by Morningstar/MarketWatch. It meets the valuation-upside-capacity screen through a low earnings multiple, but it does not currently meet the high-growth, margin-inflection, or clearly identified near-term catalyst screens as strongly as the other selections. Its inclusion reflects valuation support and liquidity rather than a confirmed operating breakout.
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 3.6 Flash High | AEHR, SOUN, SKYT, MGNI, SERV |
| Claude Sonnet 5.5 | AEHR, FCEL, ETON, NVTS, FSLY |
| Muse Spark 1.1 | INOD, UPST, SVRA, BASE, RGTI |
| GPT-6 | PGY, ARDX, INOD, FLNC, BKSY |
| DeepSeek | AQST, CRMD, MLYS, IMNM, ACHR |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.